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Abstract: Ciclesonide is a novel corticosteroid (CS) for the treatment of asthma and allergic 
rhinitis. After administration, the parent compound ciclesonide is converted by intracellular 
airway esterases to its pharmacologically active metabolite desisobutyryl-ciclesonide (des-CIC). 
We investigated the in vitro activation of ciclesonide and further esteriﬁ  cation of des-CIC to 
(mainly) des-CIC oleate in several human target organ test systems. Human precision-cut lung 
slices, alveolar type II epithelial cells (A549), normal bronchial epithelial cells (NHBE), and 
nasal epithelial cells (HNEC) were incubated with ciclesonide. Enzymes characterization and 
the determination of the reversibility of fatty acid esteriﬁ  cation was investigated in HNEC 
and NHBE. Ciclesonide was taken up and converted to des-CIC in all cellular test systems. 
Intracellular concentrations of des-CIC were maintained for up to 24 h. Formation of des-CIC 
oleate increased over time in HNEC, A549 cells, and lung slices. The formed des-CIC fatty 
acid conjugates were reconverted to des-CIC. Increasing concentrations of carboxylesterase 
and cholinesterase inhibitors progressively reduced the formation of metabolites. The results 
derived from these studies demonstrate the activation of ciclesonide to des-CIC in the upper 
and lower airways. The reversible formation of des-CIC fatty acid conjugates may prolong the 
anti-inﬂ  ammatory activity of des-CIC and may allow for once-daily dosing.
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Introduction
Asthma is one of the most common chronic inﬂ  ammatory disorders of the airways 
and is characterized by airway obstruction, inﬂ  ammation and hyper-responsiveness 
resulting from complex interactions among inﬂ  ammatory cells, mediators, and the cells 
and tissues of the airways. International and national treatment guidelines recommend 
the use of inhaled corticosteroids (CS) as ﬁ  rst-line therapy for patients with asthma 
(NIH 1997; GINA 2005).
Inhaled CS effectively treat asthma due to their potent anti-inﬂ  ammatory effect, 
altering the production of mediators involved in airway inﬂ  ammation and hyper-
responsiveness (GINA 2005; Barnes 1990). The reductions in airway inﬂ  ammation 
and hyper-responsiveness improve lung function and asthma symptoms, and reduce 
acute exacerbations requiring urgent care and rescue medication use (Blais et al 
1998; Georgitis 1999; GINA 2005). In addition, early intervention with inhaled CS in 
persistent asthma has been shown to improve clinical outcomes, which is thought to 
be due to their beneﬁ  cial effects on airway remodeling (NIH 1997; Canonica 2006).
Allergic rhinitis is deﬁ  ned as intermittent (or seasonal) or persistent (or perennial) and 
affects 10% to 30% of the world’s population (Skoner 2001; Berger 2003; CKS 2007). 
The most common symptoms of allergic rhinitis include sneezing, itching, rhinorrhea, 
and nasal blockage. According to the Allergic Rhinitis and its Impact on Asthma 
guidelines, allergic rhinitis is a major chronic respiratory disease that is increasing in 
prevalence; reduces quality of life, performance, and productivity; and is a signiﬁ  cant Journal of Asthma and Allergy 2008:1  12
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risk factor for asthma (Bousquet et al 2001, 2004). Intranasal 
CS are the most effective treatment option in patients with 
moderate or severe allergic rhinitis and provide effective relief 
of nasal symptoms and congestion because of their potent 
anti-inﬂ  ammatory activity (Gelfand 2004; Storms 2004).
Ciclesonide is a new-generation CS currently developed 
and approved for the treatment of asthma and allergic rhinitis. 
Ciclesonide is administered via a metered-dose inhaler using 
hydroﬂ  uoroalkane (HFA) as the propellant or in a hypotonic for-
mulation as nasal spray. In contrast to other CS that bind directly 
to the corticosteroid receptor, eg, budesonide, ciclesonide is a 
prodrug with almost no receptor binding afﬁ  nity. Intracellular 
airway esterases convert ciclesonide to its pharmacologically 
active metabolite desisobutyryl-ciclesonide (des-CIC), which 
has a 100-fold higher binding afﬁ  nity for the corticosteroid 
receptor than the prodrug (Dietzel et al 2001; Dent 2002).
Another feature that is associated with an improved 
efﬁ  cacy of CS is the ability to form highly lipophilic fatty acid 
esters. The conjugation of a corticosteroid with fatty acids 
in the pulmonary tissue provides a mechanism by which the 
drug can be retained in the lung for a prolonged period of 
time (Edsbäcker and Brattsand 2002). A hydroxyl group at 
position C-21 is required for the formation of the ester bond 
between the corticosteroid and the fatty acid (Tunek et al 
1997). Budesonide and des-CIC have a hydroxyl group at 
the C-21 position and conjugates with oleic and palmitic acid 
have been found in vitro in rat trachea and lung tissues (Nave 
et al 2004; Lexmüller et al 2007). Uptake and metabolism of 
ciclesonide are illustrated in Figure 1.
The aim is to review the metabolism data supporting the 
activation of ciclesonide and esteriﬁ  cation of des-CIC and 
to discuss the clinical implications this may have on asthma 
and allergic rhinitis treatment.
Methods
All methods described in this section are brieﬂ  y summarized 
as they are previously published.
Human nasal epithelial cells (HNEC) in culture dishes 
were incubated for 1 h at 37 °C with growth medium 
containing ciclesonide (1 × 10−7 mol/L). Cells were 
Figure 1 Intracellular activation of ciclesonide and reversible esteriﬁ  cation of des-CIC. Reprinted from Nave R, Meyer W, Fuhst R, et al 2005b. Formation of fatty acid conjugates 
of ciclesonide active metabolite in the rat lung after 4-week inhalation of ciclesonide. Pulm Pharmacol Ther, 18:390–6. Copyright © Elsevier.
Abbreviations: GCS, glucocorticosteroid; des-CIC, desisobutyryl-ciclesonide.Journal of Asthma and Allergy 2008:1 13
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washed and incubated for a further 0.5, 3, 6, and 24 in 
ciclesonide-free medium (Sato et al 2007a). To investigate 
reversibility of des-CIC, HNEC were incubated with 10–6 
mol/L des-CIC for 6 h. Cells were washed and incubated in 
des-CIC-free medium for 3, 6, and 24 h. Cells were collected 
at 0, 3, 6, and 24 h; medium was collected at 1, 3, 6, and 24 
h (Sato et al 2007a).
Normal human bronchial epithelial (NHBE) cells were 
cultured in culture dishes and incubated for up to 24 h 
with ciclesonide (5 × 10−6 mol/L) (Mutch et al 2007). To 
investigate reversibility of des-CIC, NHBE were incubated 
with des-CIC (1 × 10−6 mol/L) for 6 h. Cells were washed 
and incubated in des-CIC free medium up to 24 h. Cells 
were collected at 0, 3, 6 and 24 h; medium was collected at 
1, 3, 6 and 24 h and replaced by fresh medium at 1, 3 and 
6 h (Nonaka unpublished data).
Human alveolar type II epithelial (A549) cells in culture 
dishes were incubated for 3, 5, 10, 20, or 30 min (uptake), or 
for 1 h (metabolism) at 37 °C with growth medium containing 
ciclesonide (2 × 10−8 mol/L). To investigate metabolism, 
cells were washed and incubated for a further 3, 6, and 24 
in ciclesonide-free medium (Nonaka et al 2007).
Human precision-cut lung slices were incubated at 
37 °C with ciclesonide (1 × 10−5 mol/L) or 14C-ciclesonide 
(2.5 × 10−5 mol/L) (Nave et al 2006a, 2007).
To identify the esterases involved HNEC and NHBE 
were preincubated for 30 min with the chemical inhibitors 
(ﬁ  nal concentration 1 × 10−5 mol/L for the inhibition of 
esterases) paraoxon, bis(p-nitrophenyl)phosphate (BNPP), 
tetraisopropyl pyrophosphoramide (iso-OMPA), eserine, 
4-hydroxymercuribenzoic acid sodium salt (PMB), and 
ethylenediamine tetraacetic acid (EDTA).
Ciclesonide (5 × 10−6 mol/L) was added to start the reac-
tion and cells were incubated for 2 (NHBE) or 6 h (HNEC) 
(Mutch et al 2007; Sato et al 2007a).
For all investigations, ethanolic extracts of harvested cells 
or tissues were analyzed using high performance liquid chro-
matography (UPLC) with ultraviolet (UV), radio, or tandem 
mass spectrometric (LC-MS/MS) detection. In general for 
all cell test systems, ethanol was added to each medium 
harvested, and this mixture was vortex-mixed, centrifuged, 
and the extracted supernatant was harvested. After cells 
frozen in the plates were gradually thawed, the cells were 
frozen by liquid nitrogen again. After the freeze/thaw cycle 
was repeated again, ethanol containing 0.1% Tween 80 was 
added to each well in order to extract the analyte from cells. 
The samples were centrifuged and the extracted supernatant 
was harvested. For lung slices, samples of the incubation 
medium were prepared by mixing the same volume of 
medium with a solution (0.2 M ZnSO4/acetonitrile, 1:1) for 
precipitation. Following centrifugation, the supernatant was 
assayed by HPLC. Tissue samples were homogenized in 
methanol using ultrasonic treatment and were centrifuged. 
After centrifugation, supernatant was dried and resuspended 
in methanol before analysis.
Concentrations of ciclesonide, des-CIC, and des-CIC 
fatty acid conjugates (des-CIC-oleate and des-CIC-palmitate) 
in the sample extracted from the culture medium, cells, or 
slices were analyzed by liquid chromatography with a UV 
detector monitoring at 242 nm or with LC-MS/MS. Ethanol 
solutions containing ciclesonide, des-CIC, des-CIC-oleate, 
and des-CIC-palmitate were used as standard solutions. 
Deuterated des-CIC was used as an internal standard for LC-
MS/MS. Water/ethanol gradient systems were run and these 
systems were suitable for assaying the parent compounds 
and the metabolites.
Results
Cellular uptake of ciclesonide
A fast uptake of ciclesonide was conﬁ  rmed in all cellular 
test systems. The earliest timepoint used was 3 min in the 
investigation with A549 cells. The uptake of ciclesonide in 
A549 cells was almost complete within 10 min after the start 
of the incubation period (Table 1) (Nonaka et al 2007).
The uptake of ciclesonide into human lung and liver slices 
was investigated using radiolabeled ciclesonide. Quantiﬁ  ca-
tion of radiolabeled ciclesonide and its metabolites within 
the tissue were possible following combustion (Nave et al 
2006a). At late timepoints levels of radioactive drug-related 
material in human lung tissue were 7-fold higher than in the 
liver tissue. In the lung slices, recovered radioactivity was 
up to 60% of the spiked amount of drug.
Table 1 Uptake of ciclesonide into A549 cells (derived from data 
of Nonaka et al 2007)
Incubation time
(min)
Mean concentration
(pmol/dish)
Standard
deviation
3 15.51 2.62
5 18.19 2.34
10 37.32 23.51
20 35.31 9.09
30 50.33 5.12
Notes: Intracellular concentrations of total ciclesonide (sum of ciclesonide, 
desisobutyryl-ciclesonide [des-CIC], and des-CIC fatty acid esters) in  A549 cells during 
incubation with 2 × 10−8 M ciclesonide (5 dishes per time point).Journal of Asthma and Allergy 2008:1  14
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Enzymolgy of ciclesonide activation
In the absence of exogenous inhibitors, ciclesonide was 
hydrolyzed to des-CIC in cellular test systems and lung tissue. 
In HNEC and NHBE cells, varying concentrations of carbo-
xylesterase- and cholinesterase-speciﬁ  c inhibitors (BNPP, 
iso-OMP) caused a dose-dependent decrease in ciclesonide 
metabolism (Mutch et al 2007; Sato et al 2007a). BNPP, 
iso-OMP, and non-speciﬁ  c inhibitor paraoxon (1 × 10−5 mol/L) 
decreased the hydrolysis of ciclesonide to des-CIC by more than 
75% (Table 2). Arylesterase- and A-esterase-speciﬁ  c inhibitors 
(PMB, EDTA) did not affect ciclesonide metabolism in HNEC. 
A similar result was observed in NHBE cells (Table 2).
Formation of des-CIC fatty acid esters
In A549 cells, HNEC, and lung tissue, des-CIC was 
detectable up to 24 h post treatment.
Intracellular formation of des-CIC fatty acid esters in 
airway epithelial cells and lung tissue increased over time 
(24 h data provided in Table 3). A higher amount of des-CIC 
oleate than des-CIC palmitate was detected in all cellular 
systems, indicating that des-CIC oleate was the main fatty 
acid ester formed (Table 3).
The quantitative analysis of all metabolites formed in lung 
slices following incubation with 14C-ciclesonide conﬁ  rmed 
the activation and formation of fatty acid esters of des-CIC 
(Nave et al 2006a).
Reversibility of esteriﬁ  cation
The total amount of intracellular des-CIC fatty acid esters 
decreased over 24 h to 20% of the original concentration, 
whereas the total amount of des-CIC increased over time in 
the medium (Figure 2). The recovery at all timepoints was 
approximately 100%, indicating that des-CIC is reconverted 
from des-CIC-oleate.
Similar results were obtained in HNEC (Sato et al 
2007a). The total amount of des-CIC increased during the 
post-treatment period and accounted for approximately 85% 
of total analytes 24 h after treatment. However, the total 
amount of des-CIC fatty acid conjugates declined over time 
and represented only 15% of total analytes 24 h post treat-
ment. Intracellular amounts of des-CIC and des-CIC fatty 
acid conjugates decreased while des-CIC progressively 
accumulated in the medium. Extracellular concentrations 
of des-CIC-oleate and des-CIC-palmitate were almost 
undetectable at all timepoints post-treatment.
Conclusions
The results presented here conﬁ  rm that ciclesonide was effec-
tively taken up and converted to its pharmacologically active 
metabolite des-CIC in vitro in human cellular test systems 
and human lung tissue. Despite the variety of test systems and 
analytical methods used, the results conﬁ  rm that activation 
of ciclesonide occurs by a similar mechanism in the upper 
and lower airways. The rapid conversion of ciclesonide 
to des-CIC is mediated mainly by carboxylesterases and 
cholinesterases. The presence of des-CIC for up to 24 h and 
the reversible formation of des-CIC fatty acid esters, which 
serve as a slow-release pool of active drug, may prolong the 
anti-inﬂ  ammatory activity of ciclesonide and may support a 
24-h effect with once-daily dosing in patients with asthma 
and allergic rhinitis.
Discussion
After uptake into the cell ciclesonide, is converted to des-CIC 
via cleavage of an ester bond, and therefore it was postu-
lated that esterases may be involved in the reaction. Inves-
tigations were performed to characterize the enzymology 
of ciclesonide metabolism in human liver microsomes. 
BNPP and SKF 525-A, respectively, inhibited des-CIC 
formation from 14C-ciclesonide by 82% and 49% and M2/M3 
(hydroxy-metabolite) formation by 82%–84% and 87%–89%. 
It is concluded that the human hepatic metabolism of cicle-
sonide is primarily catalyzed by one or more esterases to des-
CIC and then subsequently metabolized by CYP3A4 (Peet 
et al 2005). Further esterase characterization was done in 
HNEC and NHBE cells. In both test systems carboxylesterase 
and cholinesterase could be identiﬁ  ed as major esterases 
involved in the ﬁ  rst step of the ciclesonide metabolism 
Table 2 Inhibition of esterases in HNEC and HNBE cells (derived 
from data of Mutch et al 2007; Sato et al 2007a)
Inhibitor Target esterase Mean + SEM 
% control activity
HNEC NHBE
Paraoxon CarbE, BChE, AChE 25.0 ± 0.3 16.7 ± 0.7
BNPP CarbE 24.9 ± 0.3 20.0 ± 3.8
Iso-OMPA CarbE 29.3 ± 0.6 22.3 ± 3.8
Eserine AChE 48.2 ± 0.3 28.7 ± 3.7
PMB ArE 103.8 ± 0.8 90.3 ± 17.3
EDTA A-E 105.8 ± 0.3 78.7 ± 4.7
Notes: data are expressed as percentage inhibition of control (no inhibitior) 
after incubation of cells with ciclesonide (5 × 10−6 mol/L) and esterase inhibitors 
(1 × 10−6 mol/L) (mean of duplicate estimations).
Abbreviations: HNEC, human bronchial epithelial cells; NHBE, normal human 
bronchial epithelial; CarbE, carboxylesterase; BChE, cholinesterase; AChE, acetylcho-
linesterase; ArE, arylesterase; A-E, A-esterase; BNPP, bis (p-nitrophenyl) phosphate; 
iso-OMPA, tetraisopropyl pyrophosphoramide; PMB, p-hydroxymercuribenzoate; 
EDTA, ethylenediaminetetraacetic acid.Journal of Asthma and Allergy 2008:1 15
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(Mutch et al 2007; Sato et al 2007a). Esterases are known 
to be present in most organs of all species; however, levels 
can vary greatly (McCracken et al 1993).
Ciclesonide was metabolized to des-CIC in nasal mucosal 
homogenates of rats, guinea pigs, rabbits, and dogs without any 
marked differences among animal species (Sato et al 2006). In 
this context it should be noted that the metabolism of ciclesonide 
in the liver is also similar among species (Gu et al 2007).
As previously mentioned, esterases, which rapidly 
hydrolyze ciclesonide, are present in human lung, nose, 
and liver, whereas ciclesonide seemed to be more stable in 
human blood, skin (data not shown), and the oropharynx. 
After inhalation of ciclesonide via a metered dose inhaler, the 
bio-activation of ciclesonide to des-CIC within the oropharynx 
was low (Nave et al 2005a; Richter et al 2005). These ﬁ  ndings 
may explain the low frequency of oropharyngeal side effects 
Table 3 Formation of des-CIC fatty acid esters in airway epithelial cells and lung tissue
Test system Substrate 
concentration 
(mol/L)
Substrate 
incubation 
time (h)
Sample 
collection 
time (h)
Mean (SD) intracellular concentrationa
CIC Des-CIC Des-CIC-
oleate
Des-CIC- 
palmitate
HNEC 1 × 10–7 1 h 24 hb 0.31 (0.07) 5.39 (0.99) 48.43 (7.46) 1.87 (0.34)
NHBE cells 1 × 10–6 1 h 24 hb 5.22 (2.53) 20.05 (1.55) 14.10 (1.38) 0.59 (0.19)
A549 cells 2 × 10–8 1 h 24 hb 2.31(0.55) 3.19 (0.38) 23.20(6.03) 0.74 (0.15)
Lung slices 1 × 10–5 24 h 24 h 2.93 (0.46) 3.23 (0.42) 3.46 (2.29)
aAmount of ciclesonide and metabolite in HNEC (pmol/dish), NHBE (pmol/well), A549 (pmol/dish), lung tissue (nmol).
bIncubation in substrate-free medium.
Abbreviations: HNEC, human bronchial epithelial cells; NHBE, normal human bronchial epithelial; des-CIC, desisobutyryl-ciclesonide.
(Derived from data of Nave et al 2007; Nonaka et al 2007; Sato et al 2007a; Nonaka unpublished data).
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Figure 2 Reversible conjugation of des-CIC with fatty acid in human bronchial epithelial cells. Data were represented as the mean ± SD from 6 wells. Time point of 0 h 
indicates the end of incubation with des-CIC for 6 h. Results at 0 h represent only the amount in the cells and results at 3, 6, and 24 h represent the sum of analyte in the 
cells and medium harvested (Nonaka unpublished data).
Abbreviations: des-CIC, desisobutyryl-ciclesonide; des-CIC FA conjugates, sum of des-CIC-oleate and des-CIC-palmitate.Journal of Asthma and Allergy 2008:1  16
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for ciclesonide compared with other inhaled CS (Engelstaetter 
et al 2004; Berger 2006).
The lipophilicity and lipid conjugation are two distinct 
pharmacokinetic parameters that can affect the absorption 
rate of a CS across pulmonary and nasal membranes and 
influence retention time in the lung and nose. Results 
from various studies have conﬁ  rmed that both ciclesonide 
and budesonide form fatty acid conjugates in a reversible 
manner (Edsbäcker and Brattsand 2002; Nave et al 2006a). 
The intracellular fatty acid conjugation of budesonide and 
des-CIC dramatically increased the lipophilicity. Des-
CIC-oleate (logD 13.0) was about 5-fold more lipophilic than 
budesonide-oleate (logD 12.3) (Nave et al 2004). Ciclesonide 
and des-CIC, however, are more lipophilic than budesonide, 
suggesting that ciclesonide may achieve greater penetration 
within the target tissue.
The intracellular localization and sustained concentration 
of intranasal CS depend to varying levels on nasal mucosal 
absorption, drug lipophilicity, glucocorticoid receptor 
afﬁ  nity, and the ability to form lipid conjugates in nasal 
epithelial cells (Esmailpour et al 2000). Retention and for-
mation of fatty acid conjugates of CS in human nasal tissue 
and its importance in treatment of allergic rhinitis have been 
reported (Bonsmann et al 2001; Petersen et al 2001).
Lexmuller et al (2007) have investigated the airway reten-
tion of various glucocorticoids using an in vitro rat trachea 
model. It was conﬁ  rmed that ciclesonide was activated to 
des-CIC and that fatty acid esters were formed. At 20 min, 
the uptake of budesonide was similar to that of ciclesonide; 
however, signiﬁ  cantly more budesonide-ester were detected 
compared with des-CIC-esters while the amount of active 
drug (budesonide and des-CIC) was comparable. This dem-
onstrates the fast activation of ciclesonide and the subsequent 
fatty acid ester formation. Furthermore, rat tracheas were 
preincubated with the esteriﬁ  cation inhibitor cyclandelate. 
Cyclandelate decreased the initial budesonide and des-
CIC-ester pools (p  0.01), and reduced the overall retention 
of budesonide at 3 h (p  0.01) but not of ciclesonide. 
Thus, esteriﬁ  cation as well as high lipophilicity prolongs 
ciclesonide airway retention.
Binding of drugs to plasma proteins is another factor that 
may affect the uptake of drugs into cells. Ciclesonide and 
des-CIC have been shown to be almost fully bound to plasma 
proteins (eg, albumin and α1-acid glycoprotein) during in 
vitro experiments (Rohatagi et al 2005) while budesonide 
has been reported to have a protein-binding rate that leaves 
approximately 12% of drug portion unbound (Ryrfeldt et al 
1982). It was demonstrated in vitro that the cellular uptake 
of corticosteroids could be affected by the protein content in 
the cell media (Janciauskiene et al 2007). The uptake of des-
CIC into human hepatocytes decreased more markedly with 
increasing serum concentrations compared with budesonide. 
However, at all corticosteroid concentrations and serum 
levels tested, the uptake of des-CIC was signiﬁ  cant greater 
than those of budesonide (p  0.05). The protein content of 
the incubation media in most of the experiments investigating 
the metabolism of ciclesonide was 0.1% bovine serum albu-
min. Other investigations on the activation of ciclesonide in 
nasal tissue from various species were performed at a ﬁ  xed 
protein concentration of 1 mg/mL (Sato et al 2006).
The in vivo situation in the nasal cavity and in the lower 
airways may be different to the in vitro situation using 
hepatocytes, as the exact protein content is not known. 
Furthermore, one should consider different formulations. 
The absorption in the lung of drugs delivered via dry powder 
is different compared with MDI. The formulation used for 
nasal administration has also been shown to inﬂ  uence the 
uptake into nasal mucosa as demonstrated for ciclesonide 
(Sato et al 2007b). The nasal tissue uptake and metabo-
lism of ciclesonide were evaluated when administered as 
a single 143 µg dose to normal Japanese white rabbits in a 
hypotonic versus an isotonic ciclesonide suspension. The 
hypotonic suspension achieved in nasal mucosa extracts 
higher concentrations of des-CIC (5.6-fold, 11.4-fold, and 
13.4-fold) and ciclesonide (25.3-fold, 34.2-fold, and 16-fold) 
at 30, 120, and 240 min post administration. Additionally, 
when administered via a hypotonic suspension, des-CIC 
was retained up to 24 h post administration and fatty acid 
esters of des-CIC were detected in nasal mucosa. These data 
suggest that a hypotonic ciclesonide suspension provides 
higher intracellular concentrations of des-CIC up to 24 h. 
Metabolism of ciclesonide in vivo in rabbit nasal mucosa 
conﬁ  rmed the formation of des-CIC-oleate and des-CIC-pal-
mitate conjugates of des-CIC in nasal mucosa, reaching their 
highest levels 8 h and 16 h post administration, respectively 
(Sato et al 2007b). The presence of fatty acid conjugates of 
des-CIC suggests that the active drug may be retained in the 
nasal mucosa as a reversible pool to exert sustained drug 
effects over time and allow once-daily dosing.
Fatty acid conjugation has also been reported for 
budesonide in nasal tissue (Tunek et al 1997; Petersen et al 
2001). We investigated the in vitro metabolism of beclometh-
asone dipropionate, budesonide, ciclesonide, and ﬂ  uticasone 
propionate in human lung precision-cut tissue slices (Nave 
et al 2007). In summary, the in vitro metabolic pathways of 
the tested CS in human lung tissue were different. While Journal of Asthma and Allergy 2008:1 17
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ﬂ  uticasone propionate was metabolically stable, the majority 
of beclomethasone dipropionate was converted to inactive 
polar metabolites. The formation of fatty acid conjugates 
was conﬁ  rmed for budesonide and des-CIC. The lipophilicity 
and lipid conjugation of the parent compounds and their 
metabolites are likely the major factors inﬂ  uencing their 
retention time in the lung (Nave et al 2007).
These data conﬁ  rm the activation of ciclesonide as well 
as the formation of fatty acid esters in vivo in the nasal 
mucosa in one animal species. Furthermore, we tested the in 
vivo metabolism of ciclesonide in the lung by exposing rats 
to inhaled ciclesonide (0.16 mg/kg/day) daily for 1 h for a 
period of 4 weeks (Nave et al 2005b). Lungs were extracted 
with ethanol 2, 5, and ∼27 h after the ﬁ  nal treatment. The 
concentrations of des-CIC and ciclesonide were determined. 
At the 2- and 5-h timepoints, fatty acid conjugates of des-CIC 
were the major metabolites (61% and 55%, respectively). 
Ciclesonide, des-CIC, and fatty acid conjugates of des-CIC 
were clearly present in lung samples the day after the last 
inhalation. This in vivo study conﬁ  rmed ciclesonide activa-
tion to des-CIC and formation of fatty acid conjugates.
In vivo data for humans on the metabolism of inhaled CS 
in the lung are limited (Van den Brink et al 2005; Drollmann 
et al 2006). A recent study investigating the disposition of 
budesonide using samples from resected pulmonary tissue 
have conﬁ  rmed that fatty acid esters of budesonide were 
formed in the human lung. Patients who were scheduled 
for whole lung or lobe resection for lung cancer inhaled 
1000 µg budesonide. Budesonide was detectable in central 
and peripheral lung tissue for about 10 h after inhalation 
whereas budesonide oleate was present for up to 43 h 
(Van den Brink et al 2005). After inhalation of a single dose 
of 1280 µg ciclesonide by patients undergoing elective lung 
surgery, ciclesonide was rapidly hydrolyzed to des-CIC in 
both central lung and peripheral lung tissue. Des-CIC and 
des-CIC oleate were the main metabolites in both lung areas, 
and at least one of the metabolites of ciclesonide (des-CIC, 
des-CIC oleate, or des-CIC palmitate) was present in the lung 
tissue samples at all study time points up to 24 h (Drollmann 
et al 2006). These in vivo ﬁ  ndings conﬁ  rm that ciclesonide 
is activated in the human lung and that budesonide as well 
as des-CIC form oleate conjugates.
In summary, ciclesonide and des-CIC fatty acid esters 
are highly lipophilic precursors of des-CIC. Although the 
majority of data presented here are based on in vitro studies, 
there is evidence that these precursors may serve as a pool 
of active drug. This slow-release pool of active drug may 
contribute to the proven efﬁ  cacy of once-daily inhaled 
ciclesonide in asthma therapy, as was shown in several 
clinical studies (Postma et al 2001; Chapman et al 2004; 
Langdon et al 2005). The same holds true for once-daily 
intranasal ciclesonide in rhinitis therapy (Nave et al 2006b; 
Ratner et al 2006; Kim et al 2007).
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